XCURHealthcare · Biotechnology

XCUR Stock Forecast: Exicure, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026

$1.58

−1.25% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 1 Aug 2026 — in the lower half.

Market cap

$10.2M

Ticker Nerd rank

35 / 100

Median analyst target

—

Analysts covering

Total return, dividends reinvested

−9.7%

−17.3%

YTD

−70.8%

−77.1%

From 52W high

−79.5%

From 52W low

+0.6%

$1.57

$7.69

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

XCUR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Exicure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Issuance

Volatility

Value

Quality

Revisions

Growth

Momentum

Size (92): Smaller than most of the companies we track.

Momentum (16): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Exicure, Inc. — and when they’d sell — is the membership.

Wall Street

XCUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XCUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Recent analyst actionsNewest first

Of the 10 most recent actions, 2 moved their price target up and 3 moved it down.

Date	Firm	Action	Rating	Target
16 Aug 2022	Chardan Capital	Maintains	Neutral	$0.25 → $2.00
13 Dec 2021	Chardan Capital	Downgrade	Neutral	$2.25 → $0.40
23 Nov 2021	Chardan Capital	Maintains	Buy	$7.00 → $2.25
17 May 2021	HC Wainwright & Co.	Maintains	Buy	$8.00 → $6.00
18 Dec 2020	BMO Capital	Initiates	Outperform	—
17 Sept 2020	Chardan Capital	Maintains	Buy	$5.00 → $7.00
20 Nov 2019	Guggenheim	Initiates	Buy	—
6 Nov 2019	H.C. Wainwright	Initiates	Buy	—
26 Mar 2019	Chardan Capital	Initiates	Buy	—
11 July 2018	Ladenburg Thalmann	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

XCUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Exicure, Inc. (XCUR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.2×
Price / sales: —
Price / book: 4.9×
EV / EBITDA: −0.9×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −145.2%
Return on assets: −32.5%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

XCUR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
XCURExicure, Inc.	$10.2M	35
INABIN8bio, Inc.	$10.1M	54
SNTISenti Biosciences Holdings, Inc.	$10.6M	37
CRISCuris, Inc.	$9.8M	39
LEXXLexaria Bioscience Corp.	$9.7M	23
TOVXTheriva Biologics, Inc.	$9.6M	40
GDTCCytoMed Therapeutics Ltd.	$10.9M	17

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XCUR appears on the weeks it earns a place.

News

Latest XCUR news & analysis

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

GlobeNewsWire · 3 Aug 2026neutral

Exicure, Inc. announced it expects to issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026 to settle a $1.0 million clinical milestone payment obligation under their License and Collaboration Agreement.

Why it matters — XCUR watchers would note the company is meeting a contractual milestone obligation by issuing equity rather than paying cash, which affects its share count.

FAQ

Frequently asked questions about XCUR stock

Is XCUR stock a buy right now?

Of the 1 analysts covering Exicure, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Exicure, Inc. 35 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XCUR?

As at 1 Aug 2026, Exicure, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

What is the XCUR stock forecast for 2030?

No analyst covering Exicure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XCUR are extrapolating price history, which says nothing about the business.

How has XCUR stock performed over the past year?

Exicure, Inc. returned -77.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Exicure, Inc. do?

Exicure, Inc. is an early-stage biotechnology company specializing in the development of nucleic acid therapies aimed at targeting ribonucleic acid (RNA) against validated biological targets.

What is the latest news on XCUR?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance". Exicure, Inc. announced it expects to issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026 to settle a $1.0 million clinical milestone payment obligation under their License and Collaboration Agreement.

Company

About Exicure, Inc.

Exicure, Inc. is an early-stage biotechnology company specializing in the development of nucleic acid therapies aimed at targeting ribonucleic acid (RNA) against validated biological targets. Founded in 2011 and headquartered in Chicago, Illinois, the company focuses on innovative treatments across several therapeutic areas including neurological disorders, oncology, immunology, and dermatology, as well as conditions like hair loss. Exicure employs advanced methods in nucleic acid chemistry and drug development, supported by a dedicated research facility with rapid and automated high-throughput nucleic acid synthesis and screening capabilities. The company's pioneering efforts position it within the biotechnology sector as a developer of novel gene-regulating and immunomodulatory drugs with potential applications in numerous health conditions.

CEO Mr. Jungsoo Kim · 2 employees · United States · https://www.exicuretx.com